Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
70.31 (1y: +60%)
Market Cap 8.87 B P/E(ttm) 93.60
Enterprise Value 8.62 B P/B 6.60
ILMN- NAS (USA)
Illumina, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$70.31
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 1.603
ILMN's Cash to Debt is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. ILMN: 1.603 )
ILMN' s 10-Year Cash to Debt Range
Min: 0.97   Max: 16544
Current: 1.6
0.97
16544
Equity to Asset 0.319
ILMN's Equity to Asset is ranked lower than
699300% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. ILMN: 0.319 )
ILMN' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.94
Current: 0.32
0.13
0.94
Interest Coverage 9.3
ILMN's Interest Coverage is ranked lower than
877192% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 73.90 vs. ILMN: 9.3 )
ILMN' s 10-Year Interest Coverage Range
Min: 7   Max: No Debt
Current: 9.3
F-Score: 7
Z-Score: 4.89
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 17.50
ILMN's Operating margin (%) is ranked lower than
892856% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. ILMN: 17.50 )
ILMN' s 10-Year Operating margin (%) Range
Min: -1775   Max: 23.4
Current: 17.5
-1775
23.4
Net-margin (%) 13.2
ILMN's Net-margin (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. ILMN: 13.2 )
ILMN' s 10-Year Net-margin (%) Range
Min: -1421.4   Max: 21.7
Current: 13.2
-1421.4
21.7
ROE (%) 11.5
ILMN's ROE (%) is ranked lower than
990098% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.30 vs. ILMN: 11.5 )
ILMN' s 10-Year ROE (%) Range
Min: -67.6   Max: 16.2
Current: 11.5
-67.6
16.2
ROA (%) 5.9
ILMN's ROA (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. ILMN: 5.9 )
ILMN' s 10-Year ROA (%) Range
Min: -33.1   Max: 13.3
Current: 5.9
-33.1
13.3
ROC (Joel Greenblatt) (%) 59.90
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.40 vs. ILMN: 59.90 )
ILMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6881.4   Max: 78.1
Current: 59.9
-6881.4
78.1
Revenue Growth (%) 15.3
ILMN's Revenue Growth (%) is ranked lower than
1176469% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.60 vs. ILMN: 15.3 )
ILMN' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 105.3
Current: 15.3
-1.5
105.3
EBITDA Growth (%) 14.8
ILMN's EBITDA Growth (%) is ranked lower than
1587300% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.70 vs. ILMN: 14.8 )
ILMN' s 10-Year EBITDA Growth (%) Range
Min: -59.7   Max: 302.7
Current: 14.8
-59.7
302.7
EPS Growth (%) 20.8
ILMN's EPS Growth (%) is ranked lower than
1923075% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.30 vs. ILMN: 20.8 )
ILMN' s 10-Year EPS Growth (%) Range
Min: -32.7   Max: 134.5
Current: 20.8
-32.7
134.5
ยป ILMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ILMN Guru Trades in Q2 2012

Ron Baron 538,908 sh (+1970.73%)
Jim Simons 394,518 sh (+1143.83%)
Mario Gabelli 33,600 sh (+239.39%)
Steven Cohen 198,524 sh (+141.22%)
Jean-Marie Eveillard 400 sh (unchged)
Louis Moore Bacon 25,000 sh (unchged)
John Hussman 810,000 sh (unchged)
George Soros Sold Out
Andreas Halvorsen Sold Out
RS Investment Management Sold Out
John Burbank Sold Out
PRIMECAP Management 1,180,400 sh (-15.99%)
Joel Greenblatt 11,850 sh (-32.49%)
Louis Moore Bacon 50,000 sh (-76.75%)
» More
Q3 2012

ILMN Guru Trades in Q3 2012

Steven Cohen 778,501 sh (+292.14%)
Ron Baron 1,242,007 sh (+130.47%)
PRIMECAP Management 1,294,100 sh (+9.63%)
Mario Gabelli 35,600 sh (+5.95%)
Jean-Marie Eveillard 400 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Joel Greenblatt 9,638 sh (-18.67%)
John Hussman 634,000 sh (-21.73%)
Jim Simons 18,718 sh (-95.26%)
» More
Q4 2012

ILMN Guru Trades in Q4 2012

Daniel Loeb 1,500,000 sh (New)
John Burbank 100,000 sh (New)
Louis Moore Bacon 140,000 sh (+180%)
PRIMECAP Management 2,076,200 sh (+60.44%)
John Hussman 1,000,000 sh (+57.73%)
Ron Baron 1,242,743 sh (+0.06%)
Jean-Marie Eveillard 400 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Mario Gabelli 28,500 sh (-19.94%)
Steven Cohen 430,018 sh (-44.76%)
» More
Q1 2013

ILMN Guru Trades in Q1 2013

Vanguard Health Care Fund 2,240,200 sh (New)
Pioneer Investments 46,300 sh (New)
Andreas Halvorsen 200,500 sh (New)
George Soros 40,000 sh (New)
Mario Gabelli 32,700 sh (+14.74%)
Jean-Marie Eveillard 400 sh (unchged)
PRIMECAP Management 2,076,200 sh (unchged)
John Burbank Sold Out
Daniel Loeb Sold Out
Ron Baron 1,216,322 sh (-2.13%)
Steven Cohen 349,414 sh (-18.74%)
John Hussman 400,000 sh (-60%)
Louis Moore Bacon 50,000 sh (-64.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2013-03-31 Sold Out 1.5%$48.36 - $55.59 $ 70.3136%0
John Hussman 2013-03-31 Reduce -60%0.9%$48.36 - $55.59 $ 70.3136%400000
Vanguard Health Care Fund 2013-03-31 New Buy0.48%$48.36 - $55.59 $ 70.3136%2240200
George Soros 2013-03-31 New Buy0.03%$48.36 - $55.59 $ 70.3136%40000
John Burbank 2013-03-31 Sold Out 0.01%$48.36 - $55.59 $ 70.3136%0
Daniel Loeb 2012-12-31 New Buy1.5%$45.19 - $56.39 $ 70.3139%1500000
John Hussman 2012-12-31 Add 57.73%0.55%$45.19 - $56.39 $ 70.3139%1000000
John Burbank 2012-12-31 New Buy0.21%$45.19 - $56.39 $ 70.3139%100000
PRIMECAP Management 2012-12-31 Add 60.44%0.07%$45.19 - $56.39 $ 70.3139%2076200
Joel Greenblatt 2012-12-31 Sold Out 0.03%$45.19 - $56.39 $ 70.3139%0
Ron Baron 2012-09-30 Add 130.47%0.22%$39.41 - $48.48 $ 70.3164%1242007
John Hussman 2012-09-30 Reduce -21.73%0.13%$39.41 - $48.48 $ 70.3164%634000
John Burbank 2012-06-30 Sold Out 0.14%$38.03 - $52.7 $ 70.3159%0
Ron Baron 2012-06-30 Add 1970.73%0.13%$38.03 - $52.7 $ 70.3159%538908
George Soros 2012-06-30 Sold Out 0.1%$38.03 - $52.7 $ 70.3159%0
Joel Greenblatt 2012-06-30 Reduce -32.49%0.03%$38.03 - $52.7 $ 70.3159%11850
Mario Gabelli 2012-06-30 Add 239.39%0.01%$38.03 - $52.7 $ 70.3159%33600
Premium More recent guru trades are included for Premium Members only!!

Guru Investment Theses on Illumina, Inc.

Baron Funds Comments on Illumina Inc. - May 01, 2013

Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis.

From Baron Fundsโ€™ first quarter 2013 letter.


Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - Aug 23, 2012

From Baron Funds' second quarter commentary:

We purchased shares of Illumina, Inc. (ILMN), a leading provider of tools and services for advanced genetic analysis. We have been following the company for several years, and we have long admired its business model and management team. During the quarter, we had an opportunity to buy Illumina's shares at a price we believed to be favorable. Roche Holding Ltd., a large Swiss-based pharmaceutical and biotech company, walked away from its hostile bid for Illumina, and Illumina's share price fell.

Illumina is the recognized leader in next generation DNA sequencing, a fast growing market with enormous potential. Until recently, DNA sequencing has been primarily used for research purposes. In the research market, Illumina's technology is the gold standard with approximately 90% of the world's DNA sequencing output currently produced on Illumina's instruments. As a result of rapid advances in technology, the cost of sequencing has declined dramatically over the past decade, and it is expected to fall to $1,000 per human genome in the near future. As the cost of sequencing declines, new applications for DNA sequencing are emerging. For example, sequencing is being used in cancer diagnosis and treatment. In some cases, a physician treating a cancer patient may have the patient's cancer tumor sequenced and may prescribe drugs that target mutations specific to the patient's cancer.

Illumina's sequencing platforms have been adopted by some well-known diagnostic reference labs, and Illumina is partnering with other labs to develop diagnostic kits. Illumina is conducting research and development on proprietary cancer diagnostic panels, initially focused on ovarian, gastric and colorectal cancers. In the future, Illumina management believes that infants will be sequenced at birth and their genetic profile will be used to manage their health throughout their lifetimes. Other market opportunities for Illumina include agricultural biology, veterinary medicine and forensics. Combined, we believe that these new markets have the potential to more than double the size of Illumina's addressable market from $4 billion to over $8 billion.

Although Illumina faces competition, and technology in this field is advancing at a rapid pace, Illumina has a proven track record of innovating, and we believe it will remain a technology leader. Illumina spends a significantly higher percentage of its revenue on research and development than its peers. The management team is highly regarded in the industry and we think has attracted some of the best talent in the field.

Illumina's business comprises an attractive "razor/blade model" in which the company sells instruments and then generates recurring revenue from consumables used with those instruments. The company generates high profit margins, which we think will expand over time as the company's revenue mix shifts to a higher percentage of high-margin consumable revenue generated from its installed instrument base. Illumina has a strong balance sheet, which provides management financial flexibility to re-invest in its business, repurchase shares or acquire new technologies.


Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina, Inc.

Baron Funds Comments on Illumina Inc.
May 1, 2013
Illumina, Inc. (ILMN) is a leading provider of genetic analysis tools, including DNA sequencing instruments and consumables. Its shares increased in December 2012 on press reports that Roche Holdings AG, a large Swiss pharmaceutical and diagnostic company, was in discussions to purchase Illumina. In early January, Illumina's shares fell after Roche's CEO was quoted in the press stating that the companies could not reach an agreement on price, and Roche was abandoning its efforts to acquire Illumina. Our investment in Illumina was not predicated on its being acquired, and we remain confident in the company's long-term prospects in the large, fast-growing market for DNA sequencing and genetic analysis. Read more...
Three Gurus Hold a Major Stake in LIFE
March 26, 2013
For the past few months, Life Technologies Corporation (LIFE), the global biotechnology company that makes DNA-sequencing equipment, laboratory instruments and lab testing products, is still in discussions with potential buyers. The company has over 50,0000 products and 5,000 patents used in cellular testing and research, forensics, food and water safety, animal health, clinical testing and numerous other applications in research science, applied science, and medical science. In its gene-sequencing sector, Life Technologies Corp. competes with Illumina Inc. (ILMN). Both California-based companies use technology that can โ€œblueprintโ€ a human beingโ€™s DNA for medical purposes in the emerging field of molecular diagnostics. Read more...
Baron Funds Comments on Illumina
August 23, 2012
From Baron Funds' second quarter commentary: Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 93.60
ILMN's P/E(ttm) is ranked lower than
934579% of the 107 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.90 vs. ILMN: 93.60 )
ILMN' s 10-Year P/E(ttm) Range
Min: 34.32   Max: 332.46
Current: 93.6
34.32
332.46
P/B 6.60
ILMN's P/B is ranked lower than
657894% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. ILMN: 6.60 )
ILMN' s 10-Year P/B Range
Min: 0.58   Max: 16.65
Current: 6.6
0.58
16.65
P/S 7.65
ILMN's P/S is ranked lower than
628930% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. ILMN: 7.65 )
ILMN' s 10-Year P/S Range
Min: 3.4   Max: 164.29
Current: 7.65
3.4
164.29
PFCF 40.90
ILMN's PFCF is ranked lower than
1063829% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.70 vs. ILMN: 40.90 )
ILMN' s 10-Year PFCF Range
Min: 13.32   Max: 138.5
Current: 40.9
13.32
138.5
EV-to-EBIT 83.3
ILMN's EV-to-EBIT is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.73 vs. ILMN: 83.3 )
ILMN' s 10-Year EV-to-EBIT Range
Min: 13.8   Max: 415.7
Current: 83.3
13.8
415.7
PEG 3.7
ILMN's PEG is ranked lower than
1694914% of the 59 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. ILMN: 3.7 )
ILMN' s 10-Year PEG Range
Min: 0.9   Max: 3.7
Current: 3.7
0.9
3.7
Shiller P/E 113
ILMN's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: vs. ILMN: 113 )
ILMN' s 10-Year Shiller P/E Range
Min: 84.23   Max: 5389
Current: 113
84.23
5389

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 84.7
ILMN's Price/Net Cash is ranked lower than
1999998% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. ILMN: 84.7 )
ILMN' s 10-Year Price/Net Cash Range
Min: 2   Max: 72.2
Current: 84.7
2
72.2
Price/Net Current Asset Value 36.1
ILMN's Price/Net Current Asset Value is ranked lower than
684931% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.00 vs. ILMN: 36.1 )
ILMN' s 10-Year Price/Net Current Asset Value Range
Min: 21.6   Max: 117.6
Current: 36.1
21.6
117.6
Price/Tangible Book 10.6
ILMN's Price/Tangible Book is ranked lower than
704225% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. ILMN: 10.6 )
ILMN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 25.8
Current: 10.6
1.5
25.8
Price/DCF (Projected) 2.6
ILMN's Price/DCF (Projected) is ranked lower than
1538460% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. ILMN: 2.6 )
ILMN' s 10-Year Price/DCF (Projected) Range
Min: 1.5   Max: 18.2
Current: 2.6
1.5
18.2
Price/Median PS Value 0.9
ILMN's Price/Median PS Value is ranked lower than
649350% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ILMN: 0.9 )
ILMN' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 17.8
Current: 0.9
0.5
17.8
Price/Peter Lynch Fair Value 3.7
ILMN's Price/Peter Lynch Fair Value is ranked lower than
3124997% of the 32 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. ILMN: 3.7 )
ILMN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.7   Max: 2.5
Current: 3.7
1.7
2.5
Price/Graham Number 5.6
ILMN's Price/Graham Number is ranked lower than
1041666% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ILMN: 5.6 )
ILMN' s 10-Year Price/Graham Number Range
Min: 3.8   Max: 5.9
Current: 5.6
3.8
5.9
Earnings Yield (Greenblatt) 1.20
ILMN's Earnings Yield (Greenblatt) is ranked lower than
94% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. ILMN: 1.20 )
ILMN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 7.2
Current: 1.2
0.2
7.2
Forward Rate of Return (Yacktman) 36.02
ILMN's Forward Rate of Return (Yacktman) is ranked lower than
1960782% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.37 vs. ILMN: 36.02 )
ILMN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.9   Max: 49.8
Current: 36.02
-4.9
49.8

Business Description

Illumina, Inc. was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company is a developer, manufacturer and marketer of integrated systems for the analysis of genetic variation and biological function. Using its proprietary technologies, it provides a line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and it expects to enter the market for molecular diagnostics. The Company's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. It develops and commercializes sequencing technologies used to perform a range of analyses, including de novo sequencing, whole genome re-sequencing, gene expression analysis and small RNA analysis. The Company's product and service offerings also include leading-edge solutions for single-nucleotide polymorphism genotyping, copy number variation, DNA methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Its tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to determine and analyze the billions of bits of genetic information needed to extract valuable medical information from advances in genomics and proteomics. During the first quarter of 2008, it reorganized its operating structure into two newly-created business segments, the Life Sciences Business Unit and the Diagnostics Business Unit. The Company's Life Sciences Business Unit includes all products and services that are mainly related to the research market, namely the product lines based on its sequencing, BeadArray, and VeraCode technologies, and its Diagnostics Business Unit focuses on the emerging opportunity in molecular diagnostics. It currently sells its products to a number of customers outside the United States, including customers in other areas of North America, Europe, and the Asia-Pacific region. The Company's manufacturing operations require a variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. The Company markets and distributes its products directly to customers in North America, Europe, and the Asia-Pacific region. The Company's main competiters are Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman Coulter, Inc.; Complete Genomics, Inc.; General Electric Company; Helicos BioSciences Corporation; Life Technologies Corporation; Luminex Corporation; Pacific Biosciences, Inc.; Roche Diagnostics Corp.; Sequenom, Inc.; and Qiagen N.V. The Company's trademarks are Illumina(r), Array of Arraystm, BeadArraytm, BeadXpress(r), CSPro(r), DASL(r), Genetic Energytm, GoldenGate(r), GoldenGate Indexingtm, GenomeStudio(r), illuminaDxtm, HiSeqtm, Infinium(r), IntelliHyb(r), iSelect(r), Making Sense Out of Life(r), Oligator(r), Sentrix(r), Solexa(r) and VeraCode(r). The
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:ILU.Germany
ยป More Articles for ILMN

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Illumina Inc. May 01 2013 
Three Gurus Hold a Major Stake in LIFE Mar 26 2013 
Baron Funds Comments on Illumina Aug 23 2012 
Baron Funds Comments on Roche Holding May 24 2012 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Illumina's "Poison Pill" Against Roche's Hostile Takeover Might Drive the Share Price Much Higher Jan 26 2012 
Illumina Inc. (ILMN) President & CEO Jay T Flatley sells 25,000 Shares Mar 14 2011 
Illumina Inc. (ILMN) Sr VP & CFO Christian O Henry sells 17,500 Shares Mar 11 2011 
Illumina Inc. (ILMN) President & CEO Jay T Flatley sells 25,000 Shares Feb 28 2011 
Illumina Inc. (ILMN) Sr VP & CFO Christian O Henry sells 17,500 Shares Feb 24 2011 

More From Our Partners
QIAGEN Downgraded to Strong Sell - Analyst Blog May 21 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial